Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease

Abstract

The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance. There were significant benefits in all other outcomes among these patients. (ClinicalTrials.gov number, NCT00268216 [ClinicalTrials.gov].).